Lisata Therapeutics (NASDAQ:LSTA) Given “Buy” Rating at HC Wainwright

HC Wainwright reaffirmed their buy rating on shares of Lisata Therapeutics (NASDAQ:LSTA – Free Report) in a research report sent to investors on Thursday morning,Benzinga reports. HC Wainwright currently has a $15.00 target price on the stock. Lisata Therapeutics Trading Down 3.1 % Shares of LSTA stock traded down $0.09 on Thursday, reaching $2.84. The […]

Leave a Reply

Your email address will not be published.

Previous post Accretive Wealth Partners LLC Sells 499 Shares of Abbott Laboratories (NYSE:ABT)
Next post Supreme Court allows multibillion-dollar class action to proceed against Meta